Male pattern hair loss: treatment evidence in 2026

Male androgenetic alopecia, commonly called male pattern hair loss, is the most frequent cause of hair loss in men and tends to progress with age. It develops through a process called follicular miniaturization, in which the hormone dihydrotestosterone (DHT), produced by the enzyme 5-alpha-reductase, gradually shrinks genetically susceptible follicles until they produce finer, shorter hairs and eventually stop [1]. The treatments with the strongest evidence work by counteracting this process or prolonging the growth phase, and they are most effective when started early and continued long term [1][2].

This article summarizes the evidence for male pattern hair loss treatment: the FDA-approved options, common off-label and adjunct approaches, and the realistic expectations and risks that should guide the decision. It is not medical advice; evaluation and treatment should be directed by a board-certified dermatologist.

What drives male pattern hair loss

The condition is multifactorial, with genetic and hormonal influences dominating. DHT shortens successive growth cycles and miniaturizes follicles in a characteristic pattern, typically a receding frontal hairline and thinning at the crown, with the back and sides usually spared because those follicles are less sensitive to DHT [1]. Diagnosis is mainly clinical and is supported by trichoscopy, where hair-diameter variation and miniaturization are visible. Because other conditions, including telogen effluvium and thyroid-related shedding, can mimic or coexist with pattern loss, a clinical evaluation matters before committing to long-term treatment. Our article on GLP-1 medications and hair shedding covers one such reversible mimic.

Treatments with the strongest evidence

Minoxidil

Topical minoxidil is FDA-approved for male pattern hair loss and prolongs the growth phase of the hair cycle [2]. Low-dose oral minoxidil has become a widely used off-label alternative for patients who find the topical solution inconvenient or irritating, and the broader hair-growth literature describes it among the evolving options [3]. Both forms require ongoing use.

5-alpha-reductase inhibitors

Oral finasteride, which blocks the conversion of testosterone to DHT, is FDA-approved and is a cornerstone of treatment, frequently combined with minoxidil [1][2]. Dutasteride blocks DHT more completely and is used off-label in some cases. Topical finasteride is an emerging option intended to reduce systemic exposure, and it appears in recent reviews of the treatment landscape [1].

Low-level light therapy

Low-level light (laser) therapy is the third FDA-cleared category and is used alone or alongside medical therapy [2][3]. It is convenient and well tolerated, though effect sizes are modest and it is generally positioned as an adjunct.

Adjunct and procedural options

Platelet-rich plasma, microneedling, and several nutraceuticals are used as adjuncts, and hair transplantation is an option for established loss with a stable donor area [2][3]. The evidence for adjuncts is more variable than for the FDA-approved core, and emerging approaches such as exosome treatments and signaling-pathway modulators remain under investigation [3]. These are best viewed as complements to, not replacements for, the established therapies.

Adverse events, limitations, and realistic expectations

• Treatment slows loss more than it restores it. Counseling should center on preserving existing hair and partial regrowth of miniaturized follicles, not full restoration of long-bald areas [1][2].
• Benefits depend on continued use. Stopping minoxidil or finasteride generally leads to gradual loss of the hair that treatment maintained.
• Finasteride sexual side effects. A minority of men report reduced libido, erectile difficulty, or reduced ejaculate volume; a systematic review of finasteride and minoxidil found finasteride more associated with reproductive effects, including reduced semen volume and libido [4]. Symptoms are usually reversible on stopping, though a small number report persistent effects, and this should be discussed before starting.
• Oral minoxidil considerations. Off-label oral minoxidil can cause unwanted body-hair growth and, less often, fluid retention or cardiovascular effects, so dosing and monitoring matter.
• Handling precautions. Finasteride and dutasteride carry pregnancy-related handling cautions; women who are or may become pregnant should not handle crushed or broken tablets.
• Slow timeline. Meaningful change is judged over six to twelve months, and early intervention preserves more hair [1].

Bottom line

The evidence-based core of male pattern hair loss treatment is minoxidil, finasteride, and low-level light therapy, often combined, with dutasteride, platelet-rich plasma, microneedling, and transplantation used as off-label or adjunct options [1][2][3]. These therapies slow progression and partially regrow miniaturized hair rather than fully reversing baldness, they require sustained use, and finasteride in particular calls for an informed discussion of sexual side effects before starting [4]. Starting early and setting realistic expectations are the keys to a durable result.

This article is for informational purposes and does not constitute medical advice.